Full-Time

Study Delivery Senior Associate

Updated on 8/24/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, Associate's, Certification

Category
Biology & Biotech (1)
Required Skills
Data Visualization
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A master’s degree, or a bachelor’s degree and 2 years of clinical execution experience, or an associate’s degree and 6 years of clinical execution experience, or a high school diploma/GED and 8 years of clinical execution experience.
  • Strong collaborative and effective communication skills within a team environment.
  • Accuracy in documentation, data tracking, and compliance checks, including identifying discrepancies and escalating them appropriately.
  • Expertise in clinical trial processes, operations, and oversight in biotech, pharmaceutical, or Contract Research Organization environments.
  • Strong skills using Microsoft Word, Excel, PowerPoint, and other relevant software for documentation, data management, and trial support.
  • Working knowledge of Clinical Trial Management Systems, electronic Trial Master Files, Electronic Data Capture, and Microsoft Office tools.
  • Ability to maintain accurate and timely data entry and manage clinical trial data flow, investigator documentation, protocol adherence, and regulatory compliance.
  • Experience overseeing vendors and suppliers.
  • Experience executing risk-based site monitoring, implementing Audit and Inspections Corrective and Preventive Actions, and applying risk mitigation to resolve operational challenges and ensure inspection readiness.
  • Cultural sensitivity and ability to collaborate across global teams.
  • Ability to recognize, highlight, and resolve issues, with curiosity and willingness to take on new tasks.
  • Understanding of the clinical and pharmaceutical drug development process and clinical trial execution principles.
  • Experience tracking and filing essential documents such as protocols, informed consent forms, and regulatory submissions to ensure version control and inspection readiness.
Responsibilities
  • Lead the development and maintenance of study-level trackers, dashboards, timelines, and tools, including vendor management, sample tracking, and drug supply planning.
  • Coordinate logistics for investigator meetings, trial events, and site communications.
  • Manage assigned study start-up activities, including system setup, access management, and document readiness.
  • Use study dashboards and reports to monitor global enrollment, data flow, and quality indicators, taking proactive action to address deviations and risks.
  • Lead delivery of assigned risk and quality management activities.
  • Track and report study progress, coordinating with the study team and vendors to resolve operational issues and maintain compliance.
  • Deliver assigned components of global recruitment and retention strategies to help achieve enrollment targets.
  • Manage Study Training system activities and oversight.
  • Build and maintain effective relationships with internal study team members, vendors, and investigator sites.
  • Act as a point of contact for routine study updates, ensuring stakeholders are informed and aligned.
  • Identify, prioritize, and escalate risks to support swift, informed decisions.
  • Lead vendor and supplier setup to ensure quality, speed, and consistency in deliverables.
  • Maintain and monitor clinical trial systems, including Clinical Trial Management Systems, ensuring accurate and timely data entry and reporting.
  • Support data collection oversight, including query resolution and reconciliation activities.
  • Manage trial documentation, including Trial Master Files, to ensure inspection readiness.
  • Contribute to best-practice development, knowledge sharing, and process improvement within the study support community.
  • Identify and highlight opportunities to streamline or automate activities within the role’s remit.
  • Support audits and inspections, including Corrective and Preventive Actions processes, and embed lessons learned across studies.
Desired Qualifications
  • Three years of work experience in a life sciences or medically related field, including one year of biopharmaceutical clinical research experience working on clinical trials in a biotechnology, pharmaceutical, or Contract Research Organization company.
  • Experience working on global clinical trials.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.